Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase ll study of mFOLFOX6 + bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer

Trial Profile

Randomized phase ll study of mFOLFOX6 + bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2019

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms ATOM
  • Most Recent Events

    • 09 Jul 2019 Safety and efficacy results published in the British Journal of Cancer.
    • 31 Aug 2018 Biomarkers information updated
    • 20 Jan 2018 Primary endpoint (Progression-free survival) has been met as per the results presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top